May 19, 2024
Headlines

Crispr

Crispr Therapeutics Q1 Earnings: Casgevy Launch Tip Of Gene Editing Iceberg (CRSP)

admin026 mins

RomoloTavani Investment Overview Crispr Therapeutics AG (NASDAQ:CRSP), the first company to secure U.S. approval for a CRISPR (“clustered, regularly interspaced, short palindromic repeats”) based gene editing therapy, Casgevy, indicated for Sickle Cell Disease (“SCD”) and Transfusion Dependent Beta Thalassemia (“TDT”), reported its Q1 2024 earnings yesterday after the bell. The reality is that Crispr Therapeutics…

Read More

CRISPR Therapeutics AG (CRSP) Annual Needham Virtual Healthcare Conference – (Transcript)

admin063 mins

CRISPR Therapeutics AG (NASDAQ:CRSP) Annual Needham Virtual Healthcare Conference Call April 10, 2024 11:45 AM ET Company Participants Samarth Kulkarni – Chief Executive Officer and Chairman Conference Call Participants Gil Blum – Needham & Company Gil Blum Good morning, everyone, and thank you for joining us on the Third Day of the Needham Healthcare Conference….

Read More

CRISPR: Upcoming Catalysts May Validate The Bull Thesis And Force A Change In Plans (CRSP)

admin023 mins

Charday Penn/E+ via Getty Images It has been over 4 years since my last CRISPR Therapeutics (NASDAQ:CRSP) article when I was hesitant about gathering a heavy CRSP position due to the ticker’s premium valuation, volatility, and the company’s young pipeline. Yet, I was optimistic about the company’s prospects of their expansive pipeline, and partnerships. Despite…

Read More

CRISPR Therapeutics AG (CRSP) Presents at Citi 2024 Virtual Oncology Leadership Summit Conference (Transcript)

admin082 mins

CRISPR Therapeutics AG (NASDAQ:CRSP) Citi 2024 Virtual Oncology Leadership Summit Conference February 21, 2024 1:00 PM ET Company Participants Samarth Kulkarni – Chairman and Chief Executive Officer Conference Call Participants Yigal Nochomovitz – Citigroup Yigal Nochomovitz All right. Welcome back, everyone, to the next session of Citi’s Virtual Oncology Leadership Summit. I’m Yigal Nochomovitz, one…

Read More

Impact Of Gene Therapies And Casgevy On Crispr AG And The Industry (CRSP)

admin020 mins

Bill Oxford CASGEVY approval CASGEVY is a groundbreaking gene therapy, owned by CRISPR Therapeutics AG (CRSP) and Vertex (VRTX) specifically designed for the treatment of sickle cell disease (SCD) in individuals aged 12 and older who experience frequent vaso-occlusive crises (VOCs). Developed through a collaboration between Vertex Pharmaceuticals and CRISPR Therapeutics, CASGEVY stands out as…

Read More

Vertex And CRISPR Therapeutics: Historic Exa-cel Approval, Why Market Is Nonplussed (VRTX)

admin021 mins

Bet_Noire Investment Overview Historic Approval Validates CRISPR Gene Editing Approach News broke this afternoon that the Food and Drug Agency (“FDA”) has granted approval to a CRISPR-based gene editing therapy for the first time in history. It is an historic achievement for both Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) and CRISPR Therapeutics AG (NASDAQ:CRSP), the two companies…

Read More

CRISPR Gene Editing: Beam Therapeutics

admin017 mins

Andy/iStock via Getty Images In my third edition of my CRISPR series (see article 1 (an overview of CRISPR-Cas9) and article 2 (a comparison of CRSP and NTLA)), I want to focus on Beam Therapeutics (NASDAQ:BEAM), which is a favorite amongst investors because it uses what many believe to be a better version of gene…

Read More

Crispr Therapeutics Stock: ICER Puzzles The Prospects (NASDAQ:CRSP)

admin013 mins

jupiter55/iStock via Getty Images Introduction CRISPR Therapeutics (NASDAQ:CRSP) focuses predominantly on ailments such as transfusion-reliant beta thalassemia (TDT) and acute sickle cell disease (SCD). In collaboration with Vertex Pharmaceuticals (VRTX), the company is making strides with exa-cel, a therapy using CRISPR gene-editing. Prominent regulatory bodies, like the FDA and European Medicines Agency, are currently evaluating…

Read More